Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Work In Process (2022 - 2025)

Fortress Biotech has reported Work In Process over the past 4 years, most recently at $435000.0 for Q1 2025.

  • Quarterly results put Work In Process at $435000.0 for Q1 2025, down 45.96% from a year ago — trailing twelve months through Mar 2025 was $435000.0 (down 45.96% YoY), and the annual figure for FY2024 was $367000.0, down 58.48%.
  • Work In Process for Q1 2025 was $435000.0 at Fortress Biotech, up from $367000.0 in the prior quarter.
  • Over the last five years, Work In Process for FBIO hit a ceiling of $2.7 million in Q2 2022 and a floor of $26000.0 in Q3 2022.
  • Median Work In Process over the past 4 years was $495500.0 (2022), compared with a mean of $707416.7.
  • Biggest five-year swings in Work In Process: skyrocketed 1661.54% in 2023 and later crashed 70.19% in 2024.
  • Fortress Biotech's Work In Process stood at $395000.0 in 2022, then surged by 123.8% to $884000.0 in 2023, then plummeted by 58.48% to $367000.0 in 2024, then increased by 18.53% to $435000.0 in 2025.
  • The last three reported values for Work In Process were $435000.0 (Q1 2025), $367000.0 (Q4 2024), and $296000.0 (Q2 2024) per Business Quant data.